The reimbursement challenge for Keytruda continues this year. Although no results have been made, the company seems to be on a steady course in applying for reimbursement.

According to industry sources, 6 indications of MSD Korea’s PD-1 inhibitor immuno-oncology drug Keytruda (pembrolizumab) are expected to be submitted to the Health Insurance Review and Assessment Service's Cancer Disease Review Committee for reimbursement deliberations at the committee’s first meeting this year.

Keytruda, which attracted attention in June last year for submitting an application for coverage expansion for 13 indications, has so far received a re-deliberation decision for 7 of the indications - triple-